Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial.

Puls M, Zeisberg EM, Placzek M, Beuthner BE, Jacob CF, Steinhaus KE, Lange T, Tostmann R, Schnelle M, Schuster A, Hasenfuß G, Friede T

Open source

DOI: 10.1093/eschf/xvag083
Published: 2026 May 5
Container: ESC heart failure
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/eschf/xvag083,
  title = {Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial.},
  author = {Puls M and Zeisberg EM and Placzek M and Beuthner BE and Jacob CF and Steinhaus KE and Lange T and Tostmann R and Schnelle M and Schuster A and Hasenfuß G and Friede T},
  year = {2026},
  journal = {ESC heart failure},
  doi = {10.1093/eschf/xvag083},
  url = {https://doi.org/10.1093/eschf/xvag083}
}

RIS

TY  - JOUR
TI  - Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial.
AU  - Puls M
AU  - Zeisberg EM
AU  - Placzek M
AU  - Beuthner BE
AU  - Jacob CF
AU  - Steinhaus KE
AU  - Lange T
AU  - Tostmann R
AU  - Schnelle M
AU  - Schuster A
AU  - Hasenfuß G
AU  - Friede T
PY  - 2026
JO  - ESC heart failure
DO  - 10.1093/eschf/xvag083
UR  - https://doi.org/10.1093/eschf/xvag083
ER  -

APA

M, P., EM, Z., M, P., BE, B., CF, J., KE, S., T, L., R, T., M, S., A, S., G, H., & T, F. (2026). Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial.. ESC heart failure. https://doi.org/10.1093/eschf/xvag083

Source records

pubmed · retrieved 2026-09-25T07:28:48.534Z